While the drugs certainly contribute to weight loss and health gains, they also cause a decline in muscle that some doctors find concerning. In trials of Wegovy, up to 40% of weight loss was from a decrease in lean or fat-free mass, rather than excess fat. In addition, quitting the drugs can mean adding back the pounds.

A U.S. federal judge has sided with a U.S. regulator's decision last year to take Eli Lilly’s blockbuster weight loss and diabetes drugs Zepbound and Mounjaro off a list of medicines in short supply,

A new federal ruling means that patients will no longer have access to cheaper versions of Eli Lilly weight loss and diabetes drugs from compounding pharmacies.

While the primary target for these medication is weight loss, it’s not the only metric by which the drugs should be evaluated and prescribed. Glass points out that obesity is a complex condition, and people with obesity often have other health issues as well, related to the heart, kidney, and liver. “It’s not just about weight,” he says.

The Trump administration on Monday singled out powerful new weight-loss drugs including Wegovy and Zepbound as targets in its push to lower prescription drug prices. President Donald Trump's executive order demands that drugmakers cut prices on their products in the coming months to hew more closely to what they charge in other developed countries,

CVS Caremark decided to stop offering one product in favor of another for weight loss, the latest example of insurance-imposed limits that disrupt treatment.

Some of the bankrupt company’s closest rivals, newer telehealth firms, face a new challenge of their own as federal regulators crack down on the